As the investment division of Viva Biotech Holdings (1873.HK), Viva BioInnovator is dedicated to the identification and success of early-stage biotech start-ups. We utilize our investment platforms such as in-kind investment or incubator services to fulfill our commitment of operating a collaborative platform for innovative ideas and biotech companies with transformative potential. We prefer to invest during seed or A rounds with an average investment range of $500 K to $5 M.
By leveraging our rich industry experience and technical advantages, VBI provides R&D, working sites, logistic support, industrial docking, investor connections, and more to accelerate the transformation and commercialization of new drug discovery around the world. Since the end of 2019, VBI has incubated/ invested in close to 50 early-stage biotech startups and has plans to maintain an evergreen strategy by adding new projects every year.
We Assess Investment Opportunities Based on Four Key Criteria
We insist the founders have strong integrity and a track record of company building and new drug R&D.
The “idea” needs to be innovative.
There must be a true unmet medical need.
There must be significant market potential 5-10 years in the future.